E-DRUG: Reminder: webinar tomorrow (Mar 26) - How much does it cost to develop a new medicine? Public v private investments in the TB drug bedaquiline
----------------------------------------------------------------------------------
Dear all,
(apologies for cross-posting)
Just a quick reminder that the webinar below is taking place tomorrow,
March 26,
4-5 pm CET, 11am-12pm EDT. To attend, please register here:
https://zoom.us/webinar/register/5515851340128/WN_lvhrTx_KSEWM6GKWFuwooA
The focus of the webinar is on the drug bedaquiline for tuberculosis, with
findings and discussions also very relevant for current debates on R&D
funding and access to any drugs and health technology for covid19.
We hope you will be able to join us for this discussion. For those who
can't join the live webinar, a recording will be available a few days after
at: https://www.knowledgeportalia.org/webinars
---------------------
How much does it cost to develop a new medicine? Public versus private
investments in the TB drug bedaquiline
Thursday, March 26, 4pm - 5pm CET |11am - 12pm EDT
To join the webinar, please register here:
https://zoom.us/webinar/register/5515851340128/WN_lvhrTx_KSEWM6GKWFuwooA
Speakers:
Dzintars Gotham, independent researcher
Lindsay McKenna, TB Project Co-Director, Treatment Action Group (TAG)
Research:
Conference abstract: Public investments in the clinical development of
bedaquiline, D Gotham, L McKenna, M Frick, E Lessem
https://hyderabad.worldlunghealth.org/wp-content/uploads/2019/11/20191101_UNION2019_Abstracts_Final.pdf,
p. S104.
The question of how much it costs and who contributes to the development of
new medicines is at the core of current public and policy debates. It has
implications for determining what would be a fair price, as well as for
designing innovative approaches on how to better incentivize innovation.
However, despite a few estimates, there is a lack of transparency on
research and development (R&D) costs and scarce information about the
different types of public investments involved. Retracing the history of
the development of specific medicines can improve our understanding of who
contributes to drug development and how.
Dzintars Gotham will present a forthcoming publication on investments in
the development of bedaquiline, the first new drug to treat tuberculosis in
50 years. Public contributions to R&D were estimated based on direct
funding of clinical studies, tax credits and deductions for the
pharmaceutical company, and revenues resulting from a US FDA Priority
Review Voucher (PRV). The study found that investments from the public and
philanthropic sector exceeded those incurred by the private sector
developer. Lindsay McKenna will discuss the research findings and their
relevance for access to and pricing of bedaquiline, as well as for
incentivizing pharmaceutical innovation as global public goods.
The webinar is free and open to the public and will be held in English.
Participants can pose questions orally or in writing, and the speakers will
respond to a selection of these during the second half of the event.
Recordings of all webinars are made available at the Knowledge Portal on
Innovation and Access to Medicines. After registering, you will receive a
confirmation email with additional information on how to join the webinar
using the Zoom platform. This event is part of the webinar series of the
Knowledge Network for Innovation and Access to Medicines, a project of the
Global Health Centre at the Graduate Institute, Geneva.
Related materials by the Knowledge Network on Innovation and Access to
Medicines (available at www.knowledgeportalia.org):
Research syntheses: Costs of pharmaceutical R&D, Public Funding of
Pharmaceutical R&D
Previous webinars:
- R&D costs of cancer medicines: how does it compare with sales income? Kiu
Tay-Teo, World Health Organization
- Public funding of drug development: contributions of the US NIH.
Ekaterina Cleary, Bentley University
- Public Funding of Biomedical R&D: What Role for Public Investment Funds
and Financial Markets? Slavek Roller, Faculty of Economics and Business,
Goethe University Frankfurt; Nadya Wells, Global Health Centre, Graduate
Institute of Geneva
- Fair pricing of medicines: what lessons from growing transparency in
vaccines prices? Suerie Moon, Global Health Centre, Graduate Institute of
Geneva; Tania Cernuschi, World Health Organization
Marcela Vieira
Researcher and Project Coordinator of the
Knowledge Network for Innovation and Access to Medicines
https://www.knowledgeportalia.org/
Global Health Centre, Research
Graduate Institute of International and Development Studies
marcela.vieira@graduateinstitute.ch